One the of most importante charactersistics of drug is a drug safety. However, there is no absolute safety. Medicines are troughly tested in controlled clinical trials with limiting population and short duration. Experience has shown that much of our knowledge about a medicine becomes available during the subsequent prescribing practice. Therefore there is a need for continued monitoring medicines after granting of product licence for a new drug (phrmacovigilance). WHO international system for drug safety monitoring as maintained by the Upsala Monitoring Centre (UMC) in Sweden, has built up vastedatabase of reports of suspect adverse drug reactions, coming from national centres in 75 countries in all of the world. The international system products valuable information from countries around the world, to support regulatory follow-up and decision-making. Emphasis is on those signals that may remain at the national level, because of small numbers or absence of local reports. The aim of the WHO's international pharmacovigilance program is a safe and rational medicines evrywhere. In Serbia as of 2005. National Medical Devices Agency is acting on behalf of the Ministry of Health as National Centre for Adverse Drug Reactions. The form for reporting adverse effects of medicines, in both pre-marketing and post-marketing phase can be found and downloaded in Word format on the Agency`s web site www.alims.sr.gov.yu.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.